Hormonal, targeted, and immunotherapy agents

Hormonal, targeted, and immunotherapy agents

Drug monograph · NCLEX study reference
Therapeutic class	Antineoplastic (hormonal, targeted, immunotherapy)
Pharmacologic class	SERM, aromatase inhibitors, GnRH agonist, antiandrogen, tyrosine kinase inhibitor, monoclonal antibodies, immune checkpoint inhibitors
Onset / peak / duration	Hormonal and oral targeted agents taken long term; antibodies and checkpoint inhibitors given by infusion at intervals.
Half-life / level	Variable; no routine level.
Routes	PO (oral), IV, IM, SubQ
High-alert (ISMP)	No
Black box warning	Yes (see Safety)
Antidote / reversal	Corticosteroids for immune-related checkpoint reactions; supportive care.
Pregnancy / lactation	Contraindicated.

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

Hormonal, targeted, and immunotherapy agents — Antineoplastic (hormonal, targeted, immunotherapy); SERM, aromatase inhibitors, GnRH agonist, antiandrogen, tyrosine kinase inhibitor, monoclonal antibodies, immune checkpoint inhibitors.

Identification

• Therapeutic class: Antineoplastic (hormonal, targeted, immunotherapy).
• Pharmacologic class: SERM, aromatase inhibitors, GnRH agonist, antiandrogen, tyrosine kinase inhibitor, monoclonal antibodies, immune checkpoint inhibitors.

Pharmacology

• Mechanism of action: Block hormone-driven growth (tamoxifen, aromatase inhibitors, leuprolide, bicalutamide), inhibit specific tumor signaling (imatinib, trastuzumab), or release the immune system against cancer (pembrolizumab, nivolumab).
• Onset / peak / duration: Hormonal and oral targeted agents taken long term; antibodies and checkpoint inhibitors given by infusion at intervals.
• Half-life / therapeutic level: Variable; no routine level.

Clinical use

• Indications: Hormone-receptor-positive breast cancer (tamoxifen, aromatase inhibitors), prostate cancer (leuprolide, bicalutamide), chronic myeloid leukemia and GIST (imatinib), HER2-positive cancers (trastuzumab), various solid tumors (checkpoint inhibitors), lymphomas (rituximab).
• Usual dose, route, frequency: PO daily (tamoxifen, aromatase inhibitors, imatinib, bicalutamide), IM or SubQ depot (leuprolide), IV infusion (trastuzumab, checkpoint inhibitors, rituximab).
• Maximum dose / adjustments: Adjust per protocol and organ function.

Safety

• Contraindications: Pregnancy (most), agent-specific cautions.
• Black box warning: Tamoxifen carries boxed warnings for uterine (endometrial) cancer and thromboembolic events including stroke and pulmonary embolism; trastuzumab carries boxed warnings for cardiomyopathy, infusion reactions, pulmonary toxicity, and embryo-fetal harm.
• Interactions: Tamoxifen with strong CYP2D6 inhibitors (some SSRIs reduce effect), warfarin; imatinib with CYP3A4 drugs and grapefruit; checkpoint inhibitors are immune modulating.
• Pregnancy / lactation: Contraindicated.
• High-alert: No.

Adverse effects

• Common side effects: Hot flashes and menopausal symptoms (hormonal), edema and GI upset (imatinib), fatigue, infusion reactions.
• Serious effects to report: Tamoxifen clots and abnormal uterine bleeding, trastuzumab heart failure, leuprolide tumor flare, checkpoint inhibitor immune reactions (colitis, pneumonitis, hepatitis, endocrine dysfunction).
• Antidote / reversal: Corticosteroids for immune-related checkpoint reactions; supportive care.

Nursing process

• Assessment before administration: Cardiac function (trastuzumab), pregnancy status, baseline organ function, infusion premedication.
• Interventions during therapy: Monitor cardiac function (trastuzumab); educate on immune-related symptoms (checkpoint inhibitors); manage infusion reactions.
• Monitor: Cardiac function (trastuzumab), uterine and clot signs (tamoxifen), organ-specific immune effects (checkpoint inhibitors), CBC.
• Evaluation / expected outcome: Tumor control with managed toxicity.

Patient teaching

• Patient teaching: Report leg swelling or abnormal bleeding (tamoxifen); report new diarrhea, cough, or fatigue (checkpoint inhibitors); leuprolide may briefly worsen symptoms at first.
• Notify provider if: Leg or chest symptoms, abnormal bleeding, shortness of breath, persistent diarrhea, severe fatigue.
• Administration tips: Long-term oral adherence; infusion monitoring; report immune symptoms early.